A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma

• DOI: 10.1007/s11060-024-04904-y
• Publication Date: 2025-01-06T15:12:35Z
• Authors: Kazim H. Narsinh; Karishma Kumar; Krystof Bankiewicz; Alastair J. Martin; Mitchell Berger; Jennifer Clarke; Jennie Taylor; Nancy Ann Oberhei...; Annette M. Molinaro; Manish Aghi; Nicholas Butowski
• Keywords: Adult; Male; Oligodendroglioma; Nano-liposomal irinotecan; 610; Antineoplastic Agents; Gliosarcoma; Convection; Irinotecan; Drug Delivery Systems; Phytogenic; 616; Convection enhanced delivery; Humans; CED; Aged; Liposomal irinotecan; Multiply recurrent; High grade gliomas; Brain Neoplasms; Glioma; Middle Aged; Magnetic Resonance Imaging; Neoplasm Recurrence; Local; Liposomes; Camptothecin; Female; Neoplasm Grading; Glioblastoma; Recurrent; Anaplastic astrocytoma; MRI

Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced (CED) improves by increasing intratumoral concentration. Real-time magnetic resonance imaging of infusate during CED may optimize tumor coverage. This phase 1 trial examines the safety and tolerability liposomal irinotecan gadolinium delivered via using real-time MRI guidance recurrent high-grade patients.